Taos Convention Center (meeting only) Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2001
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Chemokines and Chemokine Receptors (C3)
Organizer(s) Gregory J. LaRosa, Steven L. Kunkel, Alberto Mantovani and Barrett J. Rollins
February 16—21, 2001
Taos Convention Center (meeting only) • Taos, New Mexico USA
Abstract Deadline: Oct 16, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Dec 15, 2000
Sponsored by ICOS Corporation and Millennium Pharmaceuticals, Inc.
Summary of Meeting:
Chemokines are members of a superfamily of proteins whose primary function is to control leukocyte trafficking through lymphoid organs and other tissues. Their expression is associated with inflammatory disorders, allergic disease, infectious diseases (including HIV), atherosclerosis, and cancer. Recently, genetically modified animal models have provided in vivo proof of the pathogenetic role played by chemokines in disease, and thereby validated chemokines and their receptors as pharmacological targets. Finally, chemokine receptors have been found on a number of non-hematopoietic cells and may be important for the positioning of these cells (e.g., vascular and brain cells). Critical problems in the field include: difficulty in discovering small molecule chemokine inhibitors, indicating an incomplete understanding of chemokine ligand-receptor interactions; gaps in connecting chemokine receptor activation with the molecular machinery of cell migration; and an unclear vision of the physiology of chemokines in non-hematopoietic cells. This meeting will bring together scientists working on the molecular basis of chemokine responses with those working at the organismal level on problems of disease and the immune response. The goal is to stimulate new approaches to critical problems in chemokine research that may ultimately result in chemokine-directed therapeutics.
View Scholarships/Awards
Chemokines are members of a superfamily of proteins whose primary function is to control leukocyte trafficking through lymphoid organs and other tissues. Their expression is associated with inflammatory disorders, allergic disease, infectious diseases (including HIV), atherosclerosis, and cancer. Recently, genetically modified animal models have provided in vivo proof of the pathogenetic role played by chemokines in disease, and thereby validated chemokines and their receptors as pharmacological targets. Finally, chemokine receptors have been found on a number of non-hematopoietic cells and may be important for the positioning of these cells (e.g., vascular and brain cells). Critical problems in the field include: difficulty in discovering small molecule chemokine inhibitors, indicating an incomplete understanding of chemokine ligand-receptor interactions; gaps in connecting chemokine receptor activation with the molecular machinery of cell migration; and an unclear vision of the physiology of chemokines in non-hematopoietic cells. This meeting will bring together scientists working on the molecular basis of chemokine responses with those working at the organismal level on problems of disease and the immune response. The goal is to stimulate new approaches to critical problems in chemokine research that may ultimately result in chemokine-directed therapeutics.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
FRIDAY, FEBRUARY 16
SATURDAY, FEBRUARY 17
SUNDAY, FEBRUARY 18
MONDAY, FEBRUARY 19
TUESDAY, FEBRUARY 20
WEDNESDAY, FEBRUARY 21
Conference Program Print | View meeting in 12 hr (am/pm) time
FRIDAY, FEBRUARY 16
19:30—21:30
Keynote Address
Timothy A. Springer,
Immune Disease Institute, Harvard University, USA
Structural Rearrangements in Integrins that Regulate Leukocyte Adhesion and Trafficking
Structural Rearrangements in Integrins that Regulate Leukocyte Adhesion and Trafficking
Antonio Lanzavecchia,
Institute for Research in Biomedicine, Switzerland
Chemokine Receptors in Primary and Secondary Immune Responses
Chemokine Receptors in Primary and Secondary Immune Responses
08:00—11:00
Chemokines, Receptorology and Novel Activities I
*
Amanda E.I. Proudfoot Fichard,
Merck Serono Geneva Research Centre, Switzerland
Carlos Martinez-A,
National Center of Biotechnology-Madrid, Spain
Ligand-Mediated Chemokine Receptor Oligomerization and Its Implications
Ligand-Mediated Chemokine Receptor Oligomerization and Its Implications
Tracy M. Handel,
University of California, San Diego, USA
Structure-Function Studies of Chemokine- Receptor Interactions
Structure-Function Studies of Chemokine- Receptor Interactions
Michael Briskin,
Trammel Therapeutics, USA
Short Talk: The Bonzo Ligand CXCL16 is a Novel Transmembrane Chemokine with Multiple Potential Functions
Short Talk: The Bonzo Ligand CXCL16 is a Novel Transmembrane Chemokine with Multiple Potential Functions
Knut Biber,
AbbVie Deutschland GmbH & Co. KG, Germany
Short Talk: Characterization and mRNA Expression of a Novel MCP Chemokine Receptor (CCR12) in Mouse Glial Cells
Short Talk: Characterization and mRNA Expression of a Novel MCP Chemokine Receptor (CCR12) in Mouse Glial Cells
R. William Hipkin,
Schering-Plough Research Institute, USA
Short Talk: Human Interferon-Inducible Protein 10 (hIP-10) and Human Interferon-Inducible T Cell alpha Chemoattractant (hI-TAC) are Allotopic Ligands for Human CXCR3: Differential Binding to Receptor States
Short Talk: Human Interferon-Inducible Protein 10 (hIP-10) and Human Interferon-Inducible T Cell alpha Chemoattractant (hI-TAC) are Allotopic Ligands for Human CXCR3: Differential Binding to Receptor States
18:30—20:30
Chemokines, Receptorology and Novel Activities II
*
Amanda E.I. Proudfoot Fichard,
Merck Serono Geneva Research Centre, Switzerland
Differential Activation of Chemokine Receptors - More to Specificity than Meets the Eye
Differential Activation of Chemokine Receptors - More to Specificity than Meets the Eye
Eugene C. Butcher,
Stanford University, USA
Chemokines and the Systemic Organization of the Immune System
Chemokines and the Systemic Organization of the Immune System
08:00—11:00
Biology of Chemokines in Disease I. Cardiovascular and Rheumatological Disease.
Campbell D.K. Rogers,
Brigham and Women's Hospital, USA
Restenosis and Cardiovascular Disease: Involvement of Leukocyte Adhesion and Chemokine Activity
Restenosis and Cardiovascular Disease: Involvement of Leukocyte Adhesion and Chemokine Activity
*
Israel F. Charo,
ChemoCentryx, Inc., USA
The Role of Monocytes in Atherosclerosis and the Immune Response: Insights from the CCR2 Knockout Mouse
The Role of Monocytes in Atherosclerosis and the Immune Response: Insights from the CCR2 Knockout Mouse
Pieter H.E. Groot,
SmithKline Beecham Pharmaceuticals, UK
Short Talk: A Val6-4Ile Mutation in CCR2B is Associated with Reduced Atherosclerosis and Decreased Signalling
Short Talk: A Val6-4Ile Mutation in CCR2B is Associated with Reduced Atherosclerosis and Decreased Signalling
Daniel N. Streblow,
Oregon Health & Science University, USA
Short Talk: The Human Cytomegalovirus Chemokine Receptor US28 Mediates Vascular Smooth Muscle Cell Migration
Short Talk: The Human Cytomegalovirus Chemokine Receptor US28 Mediates Vascular Smooth Muscle Cell Migration
Alison D. Schecter,
Novartis Institute for Biomedical Research, USA
Short Talk:
Short Talk:
Katrine R. Shadidi,
, Norway
Short Talk: The Specificity of the T Cell Correlates with Its Capacity to Migrate Towards Chemokines Produced in the Inflamed Synovial Tissue
Short Talk: The Specificity of the T Cell Correlates with Its Capacity to Migrate Towards Chemokines Produced in the Inflamed Synovial Tissue
Joel Steven Pachter,
University of Connecticut Health Center, USA
Short Talk: Functional Expression of CCR2 by Human Astrocytes
Short Talk: Functional Expression of CCR2 by Human Astrocytes
16:30—18:30
POSTER SESSION 2: Biology of Chemokines in Disease, Cardiovascular and Rheumatological
Disease/Neurological Disease and Transplantation
18:30—20:30
Biology of Chemokines in Disease I. Neurological Disease and Transplantation.
William J. Karpus,
Northwestern University, USA
Chemokines and Chemokine Receptors in Autoimmune Demyelinating Disease
Chemokines and Chemokine Receptors in Autoimmune Demyelinating Disease
Wayne W. Hancock,
Children's Hospital of Philadelphia, USA
Chemokine Receptors and Transplant Rejection vs. Tolerance
Chemokine Receptors and Transplant Rejection vs. Tolerance
*
Richard M. Ransohoff,
Third Rock Ventures, USA
Short Talk: CXCL1/CXCR2 Signaling in Developmental Oligodendrogliogenesis
Short Talk: CXCL1/CXCR2 Signaling in Developmental Oligodendrogliogenesis
Lisa A. Robinson,
University of Toronto, Canada
Short Talk: Anti-CX3CR1 Antibody Blockade Prolongs Cardiac Allograft Survival
Short Talk: Anti-CX3CR1 Antibody Blockade Prolongs Cardiac Allograft Survival
08:00—11:00
Biology of Chemokines in Disease II. Pulmonary and Oncological Disease.
Timothy J. Williams,
Imperial College Faculty of Medicine, UK
Role of Chemokines in Asthma and Allergy
Role of Chemokines in Asthma and Allergy
Robert M. Strieter,
University of Virginia School of Medicine, USA
Chemokine Regulation of Angiogenesis in Cancer and Chronic Fibroproliferative Disorders
Chemokine Regulation of Angiogenesis in Cancer and Chronic Fibroproliferative Disorders
*
Frances R. Balkwill,
Barts Cancer Institute, Queen Mary University of London, UK
The Chemokine Network in Ovarian Cancer
The Chemokine Network in Ovarian Cancer
Timothy R. Traynor,
University of Michigan Medical Center, USA
Short Talk: MCP-1 is Required for the Development of T1-Type Immunity to Pulmonary Cryptococcus neoformans Infection
Short Talk: MCP-1 is Required for the Development of T1-Type Immunity to Pulmonary Cryptococcus neoformans Infection
Anja D. Müller,
Heinrich-Heine University, Germany
Short Talk: Specific Expression of Chemokine Receptors in Breast Cancer: Implications for Organ-Specific Metastasis
Short Talk: Specific Expression of Chemokine Receptors in Breast Cancer: Implications for Organ-Specific Metastasis
16:30—18:30
POSTER SESSION 3: Biology of Chemokines in Disease. Pulmonary and Oncological Disease/Infectious Disease/Chemokines in Normal Immune Function/Progress Towards Clinical Intervention
18:30—20:30
Biology of Chemokines in Disease I. Infectious Disease.
Robert W. Doms,
University of Pennsylvania School of Medicine, USA
HIV and Chemokine Receptor Conformation, Density, and Affinity
HIV and Chemokine Receptor Conformation, Density, and Affinity
Thomas J. Schall,
ChemoCentryx, Inc., USA
Title to be Determined
Title to be Determined
*
Craig Gerard,
Children's Hospital Harvard University, USA
Modulation of Infectious Disease in Chemokine Receptor Knockout Mice
Modulation of Infectious Disease in Chemokine Receptor Knockout Mice
08:00—11:00
Chemokines in Normal Immune Function
*
Alberto Mantovani,
Humanitas University, Italy
Massimo Locatti,
Istituto Clinico Humanitas IRCCS, Italy
Martin Lipp,
Max-Delbrueck-Center, MDC, Germany
Functional Organization of the Immune Response by Homeostatic Chemokines
Functional Organization of the Immune Response by Homeostatic Chemokines
Barrett J. Rollins,
Dana Farber Cancer Institute, USA
MCP-1's Influence on Inflammation and T Helper Cell Polarization
MCP-1's Influence on Inflammation and T Helper Cell Polarization
Hideki Nakano,
National Institute of Environmental Health Science, USA
Short Talk: Delayed and Enhanced T Cell Response in the plt Mutant Mice
Short Talk: Delayed and Enhanced T Cell Response in the plt Mutant Mice
Christophe Caux,
Centre Léon Bérard, France
Short Talk: Sequential Involvement of Chemokines for Immature DC Recruitment at Inflamed Epithelial Surfaces
Short Talk: Sequential Involvement of Chemokines for Immature DC Recruitment at Inflamed Epithelial Surfaces
Sergio A. Lira,
Mount Sinai School of Medicine, USA
Short Talk: Aberrant in vivo Th2 Cell Response and Impaired Eosinophil Recruitment in CCR8 Knockout Mice
Short Talk: Aberrant in vivo Th2 Cell Response and Impaired Eosinophil Recruitment in CCR8 Knockout Mice
16:00—18:00
Progress Towards Clinical Intervention
Joe E. Hesselgesser,
Gilead Sciences, Inc., USA
The CCR1 Antagonist BX 471 is Effective in Animal Models of Multiple Sclerosis and Organ Transplant Rejection
The CCR1 Antagonist BX 471 is Effective in Animal Models of Multiple Sclerosis and Organ Transplant Rejection
Julie M. Strizki,
Merck and Co., USA
Development of SCH-C, a Small Molecule Antagonist of CCR5, as a Novel Therapeutic
Development of SCH-C, a Small Molecule Antagonist of CCR5, as a Novel Therapeutic
Louise Anne Conroy,
Cambridge Antibody Technology, UK
Short Talk: Therapeutic Human Anti-Cytokine and Anti-Chemokine Antibodies Isolated by Phage Display
Short Talk: Therapeutic Human Anti-Cytokine and Anti-Chemokine Antibodies Isolated by Phage Display
Francesco Colotta,
Nerviano Medical Sciences, Italy
Short Talk: Small Organic Inhibitors of IL-8 Reduce Tissue Damage in Animal Models of Post-Ischemia Reperfusion Injury
Short Talk: Small Organic Inhibitors of IL-8 Reduce Tissue Damage in Animal Models of Post-Ischemia Reperfusion Injury
*Session Chair †Invited, not yet responded.
We gratefully acknowledge the generous grant for this conference provided by:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
